BACKGROUND: Some epidemiological studies have shown that increased @entity68 stores are associated with increased cardiovascular events. Redox-active @entity68 may contribute to lipid peroxidation, endothelial cell activation, and generation of reactive @entity26 species (especially @entity3787 radical, via Fenton chemistry). Increased oxidative stress is associated with impaired action of endothelium-derived @entity842 in @entity1 with @entity731 . METHODS AND RESULTS: To test the hypothesis that reducing vascular @entity68 stores would reverse @entity409 , we examined the effects of the @entity68 chelator @entity5532 (500 mg intra-arterially over 1 hour) on vasomotor function in forearm resistance vessels of @entity1 with @entity453 by @entity432 plethysmography. @entity1 with @entity453 had impaired endothelium-dependent vasodilation in response to @entity2710 compared with healthy control subjects (P<0.001). @entity5532 infusion decreased serum @entity68 levels (P<0.001). @entity5532 improved the blood flow response to @entity2710 in @entity1 with @entity453 (P<0.01 by 2-way repeated-measures ANOVA) but had no effect on the response to @entity1854 . In normal volunteers, @entity5532 had no effect on the response to @entity2710 . The @entity842 synthase inhibitor @entity7293 abolished augmentation of the @entity2710 response associated with @entity5532 . The @entity3787 radical scavenger @entity2656 had no effect on the @entity2710 response. CONCLUSIONS: @entity5532 improved @entity842 -mediated, endothelium-dependent vasodilation in @entity1 with @entity453 . These results suggest that @entity68 availability contributes to impaired @entity842 action in @entity731 .

@entity68 chelation improves endothelial function in XXXX with @entity453 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol'] @entity5532 :: ('MESH:D003676', 'Chemical') :: ['deferoxamine', 'Deferoxamine'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside'] @entity3787 :: ('MESH:D017665', 'Chemical') :: ['hydroxyl'] @entity7293 :: ('CHEBI:28229', 'Chemical') :: ['N(G)-monomethyl-L-arginine'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity432 :: ('MESH:D001157', 'Disease') :: ['venous occlusion'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['iron']
@entity1 :: (9606,Species) :: ['patients']
